CLASS II ONGOING Drug recall · Reported 4 Jun 2025 · FDA Enforcement Report

Theophylline (Anhydrous) Extended-Release Tablets, 600 mg recalled

Glenmark Pharmaceuticals Inc., USA is recalling Theophylline (Anhydrous) Extended-Release Tablets, 600 mg per, distributed nationwide in the US. The recall was initiated on 15 May 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLots: 19234121, 19234148, Exp Sep-30-25; Lots 19242881, 19242899, Exp Jun-30-26
NDC68462-356, 68462-380
UPC0368462380017, 0368462356012
Quantity recalled8,520 100-count bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0452-2025
FDA event ID
96867
Recalling firm
Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Classification
Class II
Status
Ongoing
Recall initiated
15 May 2025
FDA classified
28 May 2025
Reported
4 Jun 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

15 May 2025Recall initiated by company
28 May 2025Classified by FDA+13 days
4 Jun 2025Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

OOS results reported for the Dissolution (by UV) test.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited. Colvale-Bardez, Goa - 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-356-01

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

OOS results reported for the Dissolution (by UV) test.

Which lots are affected?

Lots: 19234121, 19234148, Exp Sep-30-25; Lots 19242881, 19242899, Exp Jun-30-26

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Glenmark Pharmaceuticals Inc., USA

All 141

Other Theophylline recalls

All 3